Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6595324 | 1.00 | CA12 (0.40) | CA12CA14ALDH1A1KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL5765157 | 0.98 | CA12 (0.39) | CA12CA14ALDH1A1KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL5765152 | 0.98 | CA12 (0.39) | CA12CA14ALDH1A1KMT2AMEN1 | |
| SCHEMBL1840761 | 0.91 | EPHX1 (0.48) | CA12CA14ALDH1A1KMT2AMEN1 | |
| SCHEMBL1840760 | 0.91 | EPHX1 (0.48) | CA12CA14ALDH1A1KMT2AMEN1 | |
| SCHEMBL6928093 | 0.91 | EPHX1 (0.48) | CA12CA14ALDH1A1KMT2AMEN1 | |
| SCHEMBL15000754 | 0.88 | EPHX1 (0.39) | CA12CA14ALDH1A1KMT2AMEN1 | |
| SCHEMBL27498682 | 0.88 | EPHX1 (0.39) | CA12CA14ALDH1A1KMT2AMEN1 | |
| SCHEMBL18287100 | 0.82 | ALDH1A1 (0.36) | CA12CA14ALDH1A1KMT2AMEN1 | |
| SCHEMBL19292393 | 0.82 | ALDH1A1 (0.36) | CA12CA14ALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008787-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
| EP-4551577-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | Blossomhill Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| WO-2024015262-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2024015262-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| EP-1373249-A1 | IMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION, AND THEIR USE AS ANTINFLAMATORY AGENT | Aventis Pharma Deutschland GmbH (DE) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002072573-A1 | IMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION, AND THEIR USE AS ANTINFLAMATORY AGENT. | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008787-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | KRAS, NRAS, HRAS | CA12 2545/4885CA14 2556/4885ALDH1A1 2043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.